This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, S. Articles by Gu, X.-X. Search for Related Content PubMed PubMed Citation Articles by Yu, S. Articles by Gu, X.-X.

 Previous Article  |  Next Article 

Infection and Immunity, May 2005, p. 2790-2796, Vol. 73, No. 5
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.5.2790-2796.2005

Synthesis and Characterization of Lipooligosaccharide-Based Conjugate Vaccines for Serotype B Moraxella catarrhalis

Vaccine Research Facility, National Institute on Deafness and Other Communication Disorders, Rockville, Maryland

Received 3 September 2004/ Returned for modification 18 October 2004/ Accepted 12 January 2005

Moraxella catarrhalis is an important cause of otitis media in children and respiratory tract infections in the elderly. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium that elicits bactericidal antibodies. Serological studies show that three major LOS types (A, B, and C) have been identified among clinical isolates. Our previous studies demonstrated that the type A LOS-based conjugates were immunogenic in animals. In this study, LOS from type B strain 26397 was detoxified and conjugated to tetanus toxoid (TT) or a cross-reactive mutant (CRM) of diphtheria toxin to form detoxified LOS (dLOS)-TT and dLOS-CRM, respectively, as vaccine candidates. The molar ratios of dLOS to TT and CRM in the conjugates were 43:1 and 19:1, respectively, while both weight ratios were around 0.9. The antigenicity of the conjugates was similar to that of the LOS, as determined by enzyme-linked immunosorbent assay using a rabbit antiserum to strain 26397. Subcutaneous immunization with each conjugate elicited a 180- to 230-fold rise of serum anti-LOS immunoglobulin G in mice and >2,000-fold rise in rabbits. In addition, both mouse and rabbit antisera showed elevated complement-mediated bactericidal activity against the homologous strain, and a representative rabbit antiserum showed bactericidal activity against nine of twelve clinical isolates studied. The bactericidal activity of the rabbit antiserum can be fully inhibited by the type B LOS but not the A or C LOS. These results indicate that the type B LOS-based conjugates can be used as vaccine components for further investigation.

Editor: D. L. Burns

This article has been cited by other articles:

• Yu, S., Xie, H., Datta, A., Naidu, N., Gu, X.-X. (2008). Galactose Residues on the Lipooligosaccharide of Moraxella catarrhalis 26404 Form the Epitope Recognized by the Bactericidal Antiserum from Conjugate Vaccination. Infect. Immun. 76: 4251-4258 [Abstract] [Full Text]  
• Schwingel, J. M, Michael, F. S., Cox, A. D, Masoud, H., Richards, J. C, Campagnari, A. A (2008). A unique glycosyltransferase involved in the initial assembly of Moraxella catarrhalis lipooligosaccharides. Glycobiology 18: 447-455 [Abstract] [Full Text]  
• Yu, S., Gu, X.-X. (2007). Biological and Immunological Characteristics of Lipooligosaccharide-Based Conjugate Vaccines for Serotype C Moraxella catarrhalis. Infect. Immun. 75: 2974-2980 [Abstract] [Full Text]